Vaxil Stock Today

VXL Stock  CAD 0.02  0.005  33.33%   
Market Performance
6 of 100
Odds Of Distress
Less than 50
Vaxil Bio is selling for under 0.02 as of the 5th of February 2023; that is 33.33% increase since the beginning of the trading day. The stock's lowest day price was 0.02. Vaxil Bio has 50 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Vaxil Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of January 2023 and ending today, the 5th of February 2023. Click here to learn more.
Fiscal Year End
Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company was founded in 2006 and is headquartered in Toronto, Canada. VAXIL BIO is traded on TSX Venture Exchange in Canada.. The company has 136.98 M outstanding shares of which 52.91 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions. More on Vaxil Bio
Follow Valuation Daily Balance Of Power
Check how we calculate scores

Vaxil Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vaxil Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaxil Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vaxil Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Vaxil Bio (VXL) is traded on TSX Venture Exchange in Canada and employs 2 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaxil Bio's market, we take the total number of its shares issued and multiply it by Vaxil Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vaxil Bio classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 136.98 M outstanding shares of which 52.91 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions. Vaxil Bio has accumulated about 307 K in cash with (1.08 M) of positive cash flow from operations.
Check Vaxil Bio Probability Of Bankruptcy
Vaxil Bio maintains a total of 136.98 Million outstanding shares. Vaxil Bio has 8.16 % if its outstanding shares held by insiders and 8.16 % owned by institutional holders . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation

Check Vaxil Ownership Details

Vaxil Stock Price Odds Analysis

Depending on a normal probability distribution, the odds of Vaxil Bio jumping above the current price in 90 days from now is about 28.19%. The Vaxil Bio probability density function shows the probability of Vaxil Bio stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon the stock has a beta coefficient of 1.7792. This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Vaxil Bio will likely underperform. Moreover, the company has an alpha of 1.1408, implying that it can generate a 1.14 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.02HorizonTargetOdds Above 0.02
71.72%90 days
Based on a normal probability distribution, the odds of Vaxil Bio to move above the current price in 90 days from now is about 28.19 (This Vaxil Bio probability density function shows the probability of Vaxil Stock to fall within a particular range of prices over 90 days) .

Vaxil Bio Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Vaxil Bio market risk premium is the additional return an investor will receive from holding Vaxil Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vaxil Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Vaxil Bio's alpha and beta are two of the key measurements used to evaluate Vaxil Bio's performance over the market, the standard measures of volatility play an important role as well.

Vaxil Stock Against Markets

Picking the right benchmark for Vaxil Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vaxil Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vaxil Bio is critical whether you are bullish or bearish towards Vaxil Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vaxil Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now


Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Invested in Vaxil Bio?

The danger of trading Vaxil Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vaxil Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vaxil Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vaxil Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Also, please take a look at World Market Map. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running Vaxil Bio price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Correlations
Find global opportunities by holding instruments from different markets
Please note, there is a significant difference between Vaxil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Vaxil Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.